Collegium's ADHD Pivot Accelerates, But Pain Portfolio Weighs on Guidance

Azstarys acquisition and Jornay PM momentum drive growth, yet NUCYNTA pricing hits momentum.

COLL · Earnings Call · 2026-08-06

Strategic Pivot: ADHD as the New Growth Engine

The second quarter of 2026 marked a definitive inflection in Collegium's transformation from a responsible pain management franchise into a diversified ADHD platform. The completion of the Azstarys acquisition in May, followed by rapid integration, has given the company a second differentiated stimulant to pair with Jornay PM prescriptions, which grew 13.1% year-over-year and generated $46.1 million in net revenue, up 41%. “We completed the acquisition of Azstarys in May, which now provides us with a differentiated and highly complementary medicine to Jornay PM.” — Vikram Karnani, President and Chief Executive Officer · 2026-08-06 Management's confidence in the combined portfolio is evident. Vikram Karnani noted that HCP awareness of Jornay PM has reached 67% unaided recall, approaching levels of established brands like Vyvanse and Concerta, while the company ranks #1 in reputation among ADHD-focused pharmaceutical companies. The sales force has expanded to roughly 190 reps covering about 27,000 targets, and all representatives are fully trained on both products ahead of the back-to-school season. What is particularly striking is the degree to which this quarter's narrative is a continuation of themes discussed over the past year. In the Q1 2026 call, management emphasized the proposed Azstarys acquisition and its potential to leverage existing commercial infrastructure. Now, with the deal closed, the focus has shifted to execution.

We look for assets that are in the $300 million to $500 million peak net sales range, which is a sweet spot for us. long IP, so long durability of revenues, and primarily in the U.S., given the existence of our commercial infrastructure and expertise.
Vikram Karnani, President and Chief Executive Officer · 2026-08-06

Pain Portfolio Headwinds: NUCYNTA Pricing Weighs on Guidance

While the ADHD engine is accelerating, the legacy pain portfolio provided a sobering counterpoint. Total net product revenues rose 6% to $199.9 million, but the authorized generic versions of NUCYNTA and NUCYNTA ER saw materially lower net pricing, driving the responsible pain management segment to drag on results. Xtampza ER declined 14% year-over-year, and the overall NUCYNTA franchise dropped 24%. “We are updating our 2026 financial guidance primarily to reflect lower-than-expected full-year revenue for the NUCYNTA franchise due to lower net pricing for the authorized generics.” — Colleen Tupper, Chief Financial Officer · 2026-08-06 Colleen Tupper provided detail on the authorized generic economics, noting that for NUCYNTA IR, the AG nets only 10-15% of branded net price, and for ER, 20-25%. This explains the steep decline. Management believes pricing has stabilized, but the guidance revision signals an acknowledgment that the pain portfolio's cash-generative peak is behind it. Belbuca, however, remains a bright spot, with revenue up 10% and a new formulary win adding 9 million lives starting in Q4. The company also reiterated its LOE expectations: Xtampza ER fully settled to 2033, Belbuca with an authorized generic agreement triggered by an external generic, and Teva's earliest potential Belbuca launch in January 2027.

Financial Discipline and Capital Deployment After Azstarys

The acquisition was funded with approximately $356 million of cash, leaving the company with $129.5 million in cash and marketable securities and net debt to adjusted EBITDA of about 2.1x. Adjusted EBITDA rose 8% to $113.8 million, and full-year guidance was revised to $825-855 million in product revenues with adjusted EBITDA of $445-470 million. “Azstarys revenues were $12.9 million, which reflect about a month and a half of commercial sales.” — Colleen Tupper, Chief Financial Officer · 2026-08-06 Investors have responded tepidly. The stock has been in a deep drawdown, falling from a December 2025 peak of $49.84 to a recent close around $27, a 45% decline. The 90-day trend shows a 24% decline, suggesting the market is skeptical about the durability of the pain franchise and the integration risk of Azstarys. Fundamentals from the prior quarter (Q1 2026) show total revenue of $194 million, up 9% year-over-year, with a gross margin of 60.6%. The company's revenue trajectory has been steadily upward, but the mix shift toward ADHD with lower gross-to-net is a factor to watch. Management's capital deployment strategy remains consistent: disciplined business development in adjacent CNS or rare disease, debt reduction, and opportunistic buybacks. On the call, Vikram reiterated the criteria: commercial or near-commercial assets, U.S.-based, with peak sales potential of $300-500 million and IP extending into the 2030s. This is a familiar refrain, echoed in prior calls. “We have also said before that we are open to other potential areas, but they do need to be more capital efficient.” — Vikram Karnani, President and Chief Executive Officer · 2026-02-26

Market Reaction and Outlook

The market's punishment of the stock despite an operational beat is telling. While Jornay PM and Azstarys are growing, the Street is focused on the pain portfolio's erosion and the increased leverage. The guidance cut for NUCYNTA was a negative surprise, even if the rest of the story is intact. Looking ahead, the back-to-school season will be a critical test for the combined ADHD franchise. Management's raised Azstarys guidance to $65-75 million for the partial year implies a strong run-rate, and the company expects continued momentum. For a company that has successfully navigated multiple LOEs and a strategic pivot, this quarter underscores the delicate balance between growth investment and legacy cash flow. Collegium is now a two-engine story: a fast-growing ADHD business built on two complementary brands, and a maturing pain portfolio that still provides meaningful cash flow. The market is voting with its feet, but the company's execution so far suggests the ADHD bet is paying off—just not fast enough to offset the pain portfolio's decline.